Literature DB >> 30900222

Incident Co-Morbidities in Patients with Atrial Fibrillation Initially with a CHA2DS2-VASc Score of 0 (Males) or 1 (Females): Implications for Reassessment of Stroke Risk in Initially 'Low-Risk' Patients.

Tze-Fan Chao1,2, Jo-Nan Liao1,2, Ta-Chuan Tuan1,2, Yenn-Jiang Lin1,2, Shih-Lin Chang1,2, Li-Wei Lo1,2, Yu-Feng Hu1,2, Fa-Po Chung1,2, Tzeng-Ji Chen3, Gregory Y H Lip4,5, Shih-Ann Chen1,2.   

Abstract

BACKGROUND: Oral anticoagulants (OACs) are not recommended for 'low-risk' patients with atrial fibrillation (AF). We investigated the incidences of new risk factors developing, and the temporal trends in the CHA2DS2-VASc score in initially 'low-risk' AF patients. Second, we propose a reasonable timing interval at which stroke risk should be reassessed for such AF patients.
METHODS: We studied 14,606 AF patients who did not receive anti-platelet agents or OACs with a baseline CHA2DS2-VASc score of 0 (males) or 1 (females). The CHA2DS2-VASc scores of patients were followed up and updated until the occurrence of ischaemic stroke or mortality or 31 December 2011. The associations between the prescription of warfarin and risk of adverse events once patients' scores changed were analysed. Decile values of durations to incident co-morbidities and from the acquirement of new co-morbidities to ischaemic stroke were studied.
RESULTS: During a mean follow-up of 4 years, 7,079 (48.5%) patients acquired at least one new stroke risk factor component(s) with annual risks of 6.35% for hypertension, 3.68% for age ≥ 65 years, 2.77% for heart failure, 1.99% for diabetes mellitus and 0.33% for vascular diseases. The incidence for CHA2DS2-VASc score increments was 12.1%/year. Initiation of warfarin was associated with a lower risk of adverse events (adjusted hazard ratio, 0.530; 95% confidence interval, 0.371-0.755). Among 6,188 patients who acquired new risk factors, 80% would acquire these co-morbidities after 4.2 months of AF diagnosis. The duration from the acquirement of incident co-morbidities to the occurrence of ischaemic stroke was longer than 4.4 months for 90% of the patients.
CONCLUSION: The CHA2DS2-VASc score increases in approximately 12% of initially 'low-risk' AF patients each year, and the initiation of warfarin once the score changed was associated with a better prognosis. Three to four months may be a reasonable timing interval at which stroke risk should be reassessed so that OACs could be prescribed in a timely manner for stroke prevention. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30900222     DOI: 10.1055/s-0039-1683933

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Is It Safe (and When) to Stop Oral Anticoagulation After Ablation for Atrial fibrillation? (Do We Have Enough Evidence to Solve the Dilemma?).

Authors:  José Luis Merino; Juan Tamargo
Journal:  Cardiovasc Drugs Ther       Date:  2021-09-07       Impact factor: 3.727

2.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

3.  2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.

Authors:  Tze-Fan Chao; Boyoung Joung; Yoshihide Takahashi; Toon Wei Lim; Eue-Keun Choi; Yi-Hsin Chan; Yutao Guo; Charn Sriratanasathavorn; Seil Oh; Ken Okumura; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2021-11-13       Impact factor: 5.249

4.  Anticoagulant Therapy in Initially Low-Risk Patients With Nonvalvular Atrial Fibrillation Who Develop Risk Factors.

Authors:  Sun Young Choi; Moo Hyun Kim; Kwang Min Lee; Young-Rak Cho; Jong Sung Park; Seong Woo Kim; Jin Kyung Kim; Matthew Chung; Sung-Cheol Yun; Gregory Y H Lip
Journal:  J Am Heart Assoc       Date:  2020-08-11       Impact factor: 5.501

5.  The Characteristics, Long-Term Outcomes, Risk Factors, and Antithrombotic Therapy in Chinese Patients With Atrial Fibrillation and Bioprosthetic Valves.

Authors:  Jiameng Ren; Yanmin Yang; Jun Zhu; Shuang Wu; Juan Wang; Han Zhang; Xinghui Shao
Journal:  Front Cardiovasc Med       Date:  2021-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.